On Tuesday, Europe’s medicines regulator said that they would decide by December 29 whether to grant emergency approval to a Covid-19 vaccine developed by Germany’s BioNTech and its US partner Pfizer.
The European Medicines Agency (EMA) confirmed that it had received formal applications from the vaccine maker seeking approval for experimental vaccine.
The agency said: “If the data submitted are robust enough to conclude on the quality, safety and effectiveness of the vaccine. It could conclude its assessment of the BioNTech/Pfizer shot in an extraordinary meeting on 29 December at the latest.”
European Commission spokesman Stefan de Keersmaecker told reporters that once the EMA had given regulatory permission, formal authorization from Brussels would follow very quickly, probably in a matter of days.
